RedHill Biopharma Presents Crohn’s Disease Therapeutics Program at International Research Symposium

RedHill Biopharma Presents Crohn’s Disease Therapeutics Program at International Research Symposium
Israel-based biopharmaceutical company RedHill Biopharma Ltd. recently presented its RHB-104 Phase III Crohn’s disease program at the International Research Symposium for Game Changing Concepts in Crohn’s Medicine on Sunday, August 16, 2015 in Deerfield, IL. Representing RedHill was Patrick McLean, the company’s Product Manager for RHB-104, a highly promising, experimental antibiotic combination treatment for Crohn’s disease. The symposium

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *